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The increasing of glycolysis in tumors under aerobic conditions is known as Warburg phenomenon; the activity
of the pentose phosphate pathway increases also significantly. The pentose phosphate pathway and glycolysis,
especially their first steps, and the regulatory enzyme 6-phosphofrukto-2-kinase/fructose-2,6-bisphosphatase
are influenced by cell signaling systems such as the system of circadian clock, the system of hypoxia-inducible
factor and unfolded protein response system, that allow malignant cells to adapt to stress factors such as
hypoxia, ischemia and influence of low molecular agents. The review enlightens the impact of signaling systems
on the key enzymes of glycolysis and the pentose phosphate pathway gene expression in normal cells and in
malignant cells, and their importance for survival of malignant cells under stress conditions.
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Composition and expression of hexokinase and
glucoso-6-phosphate dehydrogenase genes. Both
glycolysis and pentose phosphate pathway are impor-
tant at norm and pathology. These processes are vital;
the changes, occurring during oncotransformation of
cells, evoke considerable activation of the abovemen-
tioned metabolic pathways to satisfy the needs of cells
regarding reducing equivalents, energy and ribose for
nucleic acid synthesis. Among different pathologies,
related to glucose metabolism, the most common are
diabetes and oncological diseases, among the most
life-threatening oncological diseases are brain tumors,
in particular, glioma and glioblastoma. Increased
glycolysis in oncotransformed cells in aerobic condi-
tions is known as Warburg effect. Hexokinases and
glucoso-6-phosphate dehydrogenase are essential for
the utilization of external glucose by the cell.
The enzymes of hexokinase family in vertebrates
are encoded by independent genes, located on different
chromosomes [1]. Contrary to rats, humans have got a
pseudogene of the second hexokinase-2, located on
X-chromosome in locus q21.1. The gene of the first
isoenzyme, known as brain hexokinase, is located on
human chromosome 10, locus q22, and on rat chromo-
some 20, locus q11. Human hexokinase-1 gene, about
131 thousand b.p., contains 25 exons, including seven
alternative ones: one erythroid-specific exon and six
testis-specific exons [2]. The products of this gene are
remarkable for alternative splicing which results in the
formation of five splice-isoforms with different unique
regulatory N-terminal sites [3]. The expression of
splice-isoforms is partially tissue-specific. Alternative
non-translated exons, for instance, AltT2, are essential
for protein functioning in the nervous system; mutation
in these exons may result in neuropathy development.
The specificity of the gene is the absence of TATA-box
and the presence of inverted sequence of GATA and
erythroid promoter at 5’-end. Sequence from -275 to
-229 contains consensus motifs for transcriptional fac-
tors SP-1 and GATA, CCAAT- and GGAA-motifs,
required for the expression in erythroid cells. The
alternative transcription with further alternative spli-
cing, when an additional exon is involved in the se-
quence, causes the formation of mRNA in erythroid
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cells, encoding HK-R-specific erythroid splice-isoform
of hexokinase-1, present in erythroid cells along with
HK1 [4]. The mutations in the promoter area by AR-1
factor site result in the deficiency of this enzyme in
erythroid cells. The expression of the mentioned gene
depends on HIF-1 [5]. Motif CTGTC, remarkable for
the promoter of pyruvate kinase, was also revealed. The
element PKR-RE1 may also activate HK1 gene [6]. In
the experiment the expression of this gene in normal
and diabetic rats was induced by vegetative growth
regulator, 28-homobrassinosteroid [7].
The gene of muscle isoform of hexokinase-2 is
located on human chromosome 2, locus p13, and on rat
chromosome 4, locus q34. The gene contains 18 exons,
and it was demonstrated that the mutations in exons 4
and 17 are capable of causing the development of
insulin-independent diabetes [8]. This isoform of NA1
was called a muscle isoform, but it is expressed in many
tissues, including adipose tissue and the heart muscle
[8], the increase in its expression is remarkable for
tumor cells, including fast growing tumors [9]. The
inhibition of HK1 expression makes cells sensitive to
proapoptotic factors [10]. The promoter contains two
elements for binding p53, and the expression of this
gene is also activated at the effect of HIF and insulin
[11]. As the promoter has a sterol-regulatory element
(SRE) in position from -369 to -270, recognized by
protein SREBP-1c, the gene is activated by insulin [12].
A remarkable specificity of liver tumors is the corre-
lation between the expression of HK2 and VEGF, on
the one hand, and HIF-1 – on the other [13]. Hypoxia
enhances cell proliferation of liver tumors due to the
HK2 expression activation [14]. However, the hyper-
expression of genes of proteins, inhibiting angiogenesis
(TROP and ASTAT) is also known to cause the activati-
on of a number of glycolytic genes, including the ones,
encoding HK2 and HK1 [15]. Another activator of gly-
colytic enzyme genes is interleukin 6. Its effect is me-
diated by signal transducer and transcription activator 3
(STAT3), activating the expression of HK2 and 6-phos-
phofructo-2-kinase/fructoso-2,6-bisphosphatase-3
(PFKFB3) in murine fibroblasts and human cell lines
[16].
Hexokinase 3, or a lymphocytic form of hexokina-
se, is encoded by the gene, located on human chromo-
some 5, locus q35.2, and rat chromosome 17, locus q12
[17]. Although this isoform is called “lymphocytic”, its
expression is remarkable for liver and lungs as well,
and the aminoacid sequence is 87% homologous for
rats and humans [18]. This isoform was revealed in kid-
neys, brain and spleen; HK1 and HK3 expression in rats
depends on age and varies during the development [19].
According to other data, the expression of the above-
mentioned enzyme and VEGF, HIF-1á and HK2 corre-
lates with the accumulation of fluorine-18-stained glu-
cose by breast tumors [20]. It became possible to relate
the patterns of hexokinase expression, including hexo
kinase-3, and high-affinity transporters of glucose for
esophageal adenocarcinoma [21]. The mutations of he-
xokinase-3 gene are specific for rectal and breast
tumors [22].
Contrary to three abovementioned hexokinases
with molecular weight up to 100 kDa, the fourth hexo-
kinase, or glucokinase, is the smallest, its molecular
weight is about 50 kDa. In humans, glucokinase is
encoded by the gene, located on chromosome 7, locus
p15.3-p15.1, while in rats it is on chromosome 14, locus
q21. The gene consists of 12 exons, varying in their size
from 96 to 977 b.p., a TATA-box and the site of binding
transcriptional factor Sp1. It is assumed that the genes
of first three hexokinases were formed due to dupli-
cation and merging of glucokinase gene [23].
Three tissue-specific splice-isoforms of this enzy-
me were discovered – two in liver and one in pancreatic
-cells. Pancreatic splice-isoform differs by the first
exon, which is unique and has a modified 5’-UTR,
affecting N-end of the protein. The formed protein has a
modified N-end. Splice-isoform-2 is a dominating
splice-isoform of liver; it has a modified N-end and is
remarkable for the presence of a specific first exon of
liver isoform and the absence of the third exon, notable
for minor splice-isoform 3 of liver.
The increase in glucose level does not affect the
expression of glucokinase in -cells of pancreas. The
expression of glucokinase gene in these cells is rather
not dependent on hormones and activity of metabolism
enzymes [24]. It allows performing the function of
sensing glucose. However, the situation is more
complicated in hepatocytes – glucokinase in their com-
position is more sensitive to insulin (increasing the
expression) and glucagon, working via cAMP, evoking
glucokinase inactivation by protein kinase A [25].
ÌÀÐÓÍÈ× Ð. Þ.
The effect of insulin is caused by binding the tran-
scriptional factor HNF-4 with the promoter element
HBEs, but it is inhibited by FOXO1 factor [26]. The
promoter site of glucokinase gene in hepatocytes also
contains SRE-sequence and SP-site, interacting with
the proteins SREBP-1 and SP1, thus activating the
expression of this gene in liver in response to insulin
[27, 28]. The regulatory area of the gene contains sites
of binding factors ERR and PGC-1, activating its ex-
pression [29]. In general, the regulation of glucokinase
gene expression in hepatocytes is multi-level, as both
the transcription and mRNA of this gene are subject to
regulation [30]. Fructoso-2,6-bisphosphate is a power-
ful activator of the liver glucokinase gene expression,
as it is capable of maintaining it in the absence of insu-
lin [30], which is conditioned by the unique tissue-
specific structure of the promoter area of this gene [31].
There are many known mutations of the glucokina-
se gene, often related to different pathologies, like
diabetes [32]. For instance, polymorphism of the pro-
moter site -30 may be related to obesity [33]. Mutations
are divided into activating (T65I, W99R, V455M,
A456V) and inactivating (N161) or neutral (R397L)
[34]. Their majority occur in the center of allosteric
regulation for low-molecular compounds, located op-
posite the active center, rather than in the active center
of the enzyme [35]. The specificity lies in the fact that
the frequency of mutations, affecting kinetics, is higher
for a small domain compared to the big one (though it is
regulatory) [36]. It was demonstrated that activation
mutations usually result in hypoglycemia, while
inactivating ones – in hyperglycemia, as the function of
“sensing” glucose in -cells is impaired. There are also
mutations, hindering the formation of complexes with
the regulatory protein of glucokinase (GCKRP) and the
enzyme inactivation with the transition into the nucleus
(mutation R308W) [37]. Mutation V182M increases
the formation of complexes with GCKRP.
Contrary to the considered families of HK genes,
glucoso-6-phosphate dehydrogenase is encoded by one
gene, located on human X-chromosome, locus q28
[38]. Two splice-isoforms were characterized: a – large
isoform, consisting of 545 amino acid residues [39] that
is catalytically inactive, as it has an insert, but it may be
subject to being processed and to transform into a
smaller splice-isoform – b (515 a.r.) with a shorter
N-end, mRNA of which has a unique 5’-UTR [40]. The
latter splice-isoform is catalytically active. The pro-
moter has a TATA-box [41] and seven GC-boxes,
minimum two of which are required for the promoter
activation. The SP-1- and AP-2-like proteins bind to
these two boxes [42]. There are many known patho-
logies, related to the states of this enzyme deficiency
and its various mutations, including neonatal jaundice
[43], impairment of -cells in conditions of high
glucose content at diabetes [44], chronic erythrolysis
and megalocytic anemia [45], polycyctic ovarian
disease [46], etc. Most mutations are replacements of
one or several nucleotides in the regulatory sites or in
the exons, and natural populations are saturated with
many alleles [47].
The promoter site of the gene contains elements,
securing increased expression in response to insulin,
which also requires the activity of kinases PI3 and S6
[48]. There is observed response to palmitate and ole-
ate, which may be conditioned by one or several fac-
tors, interacting with this gene promoter: liver nuclear
factor (NF)-4, protein CAAT/, binding the enhancer,
PPAR, activator of chicken ovalbumin promoter
(COUP-TF), binding protein of cAMP-regulatory ele-
ment, and NF-B [49]. The expression of this gene is
increased in case of combined effect of insulin and
triiodothyronine, but it has no adrenergic regulation
[50]. Insignificant increase in the expression may be
mediated by HIF effect and is revealed in response to
hypoxia, but it is eliminated by antioxidants: gluta-
thione and N-acetylcysteine [51]. The expression regu-
lation via processing of the G6PDH mRNA was
determined in response to feeding or starvation of ani-
mals; here excessive feeding resulted in considerable
increase in the level and accumulation of mRNA after
splicing [52].
Therefore, the genes, encoding the enzyme of first
stages of carbohydrate metabolism, are regulated in
good coordination at the level of the organism with the
mediation of hormones, insulin and glucagon predomi-
nantly, while at the cellular level the expression is de-
fined by transcriptional factors, mainly including HIF
(in case of glycolytic pathway genes). The genes of HK
and G6PDH families, located on different chromo-
somes, are remarkable for eukaryote-typical exon-in-
tron composition and regulated by their own
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cys-regulatory elements. In majority of cases the gene
expression evokes the formation of splice-isoforms,
some of which are relatively tissue-specific.
The effect of cell signaling systems on the expre-
ssion of genes of hexokinases and glucoso-6-pho-
sphate dehydrogenase. Some genes of glucose meta-
bolism have circadian oscillation of expression, contro-
lled by the cell clock [53]. The cell clock, known as a
biological clock, is perceived as a combination of genes
and their products, forming the molecular intracellular
oscillator, regulated by the loops of negative feedback
at the level of transcription and translation. This me-
chanism secures the existence of the organism in cyc-
lically changing environment.
Molecular components of the cell clock are divided
into positive and negative elements [54]. Positive
elements form heterodimers – transcriptional factors,
and activate the transcription of negative element
genes. CLOCK and BMAL1 are found in mammals
[55]. These transcriptional factors contain structural
domains PAS (PER-Arnt-Sim) and basal HLH (basic
helix-loop-helix) [56]. Monomers form heterodimers
(CLOCK:BMAL1) and activate the transcription of
genes of the circadian clock. Negative elements in
mammals are PER1-3 and CRY1 and 2 [57]. Negative
elements inhibit the transcriptional activity of the
positive ones, reducing the yield of their protein
products. Positive elements have common homology in
the structure of domains, while negative ones do not.
The products of both positive and negative elements are
characterized by oscillation in the course of 24 hours,
and the level of products of negative elements flu-
ctuates much more. The functioning of the cell clock is
also regulated by protein kinases, kinases CK1e and
MAP phosphorylate BMAL1 in vitro [58, 59].
It was revealed that the level of mRNA expression
for circadian factors BMAL1, CLOCK and PER1 in
brain, heart, testis and lungs of rats during 24 hours
changes unevenly; these changes are tissue-specific
and coordinated with different functional values of
these tissues in metabolism of animals and possible
effect on behavior [60].
It was determined that casein kinase-1e binds to
PER1, PER2 and PER3 and phosphorylates them. It
changes the functioning of genes [61, 62], controlling
the cycle of cell division (Cyclin D1, Cyclin A,
MDM-2, c-MYC and GADD45alpha) and oncogenes as
well as genes, inhibiting growth of tumors [63]. The
abovementioned protein kinase phosphorylates BMAL1
and cryptochromes [64], participates in destabilization
of catenin-degrading complex, in the functioning of
signaling cascade TGF- [65], in the inactivation of
protein bid via its being splitting by caspase 8 [66],
phosphorylates P53 – protein, inhibiting tumor growth
[67], regulates negatively phospho-Akt via the
homologue of phosphatase and tensin PTEN [68].
In addition, there is reductive-oxidative control
over the formation of heterodimer CLOCK:BMAL1
[69]. There are data, testifying to time-dependent re-
gulation of subcellular localization of protein CLOCK
in suprachiasmatic nucleus with the important role of
BMal1 in this process [70, 71]. The regulation involves
nuclear orphan receptors of retinoic acid Rev-erb and
Ror (suppressing the expression of CLOCK and
BMAL1 [72]). The transcriptional factors DEC1 and
DEC2, containing domain bHLH, are regulated by the
circadian clock, inhibiting the transcription, initiated by
complex CLOCK:BMal1 [73].
The genes, regulated by CLOCK:BMAL1, should
contain the regulatory sequence E-box, while regulated
by Rev-erb and Ror need RORE. The genes PER1,
PER2 and PER3 are known for mammals; all Per
proteins contain domains PAS. The genes PER and
CRY have stable circadian oscillations at the levels of
mRNA and protein. Their peak is registered in the
middle of light day part [74].
There is positive and negative correlation between
mRNA for about 5,000 adipose tissue genes and mRNA
PER1. Gene expression was reduced from the morning
till the evening. Among genes, related to the circadian
system, there are many genes of lipometabolism, sy-
nthesis of cholesterol, growth factors and metabolism
of carbohydrates. They include PFKFB and its indu-
cible isoform (PFKFB-3) [75]. The level of its mRNA
is in positive correlation with the level of mRNA PER1.
PER and CRY are also capable of inhibiting the
transcription of their own genes, affecting via hete-
rodimer CLOCK:BMAL1. Since there is a reductive-
oxidative control over the formation of heterodimer
CLOCK:BMAL1 [76], there is a possibility of reverse
mediated effect of carbohydrate metabolism, in par-
ticular, glycolytic and pentose phosphate pathways on
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the cellular clock via the reductive-oxidative state of
the cytoplasm. The reductive-oxidative state of the
cytoplasm is known to change at carcinogenesis. Ho-
wever, it is hardly the only agent, causing changes in
the functioning of the cellular clock in tumors [77].
It was demonstrated that there is an inverse relation
between the cellular clock of peripheral tissues and the
level of glucose, as the increase in glucose content
reduces the level of mRNA PER1 and PER2 indirectly.
However, it was proven that this control was not related
to the change in the reductive-oxidative state of the
cytoplasm and the stabilization of dimer CLOCK:
BMAL1 (capable of activating genes, containing
E-box), rather it took place in a different way [78].
Another element of the cellular clock system –
nuclear receptor Rev-erb – controls the expression of
a number of genes of adipose tissue and liver. It was
demonstrated that Rev-erb represses the synthesis of
apolipoprotein CIII and glucoso-6-phosphatase, thus
inhibiting gluconeogenesis in liver. Indirect effect on
gluconeogenesis and glycolysis of cryptochrome-1
blocks glucagon-mediated increase in cAMP level,
decreasing the activation of cAMP-dependent protein-
kinase A, phosphorylating a considerable amount of
enzymes of carbohydrate exchange – hexokinases,
PFKFB and G6PDH [79]. According to the current
data, CLOCK directly activates the expression of
glycogen synthetase-2 with remarkable circadian
oscillations and two E-boxes in the promoter [80].
Direct regulation of steroid contra-insulin hormones,
regulating many stages of carbohydrate exchange, by
glucocorticoids, was also revealed for circadian gene
PER2, the promoter of which contains GRE sites
(sensitive to glucocorticoids). Therefore, the modula-
tion of glucose metabolism by hormones occurs via the
effect on the cellular clock, which, in its turn, affects
leptin, regulating hexokinase-3 and many other en-
zymes [80].
A great number of antioxidant system enzymes
have E-boxes in the promoter site of genes, which
testifies to the possibility of regulation by dimer
CLOCK:BMAL1 [81].
Thus, glucose metabolism at the cellular level is a
subject to the regulatory effect from the cellular clock
system. This effect may be both direct, related to the
activation of transcription of glucose metabolism
genes, and mediated – due to the effect of the cellular
clock on the kinase-phosphatase system. In addition,
there is an inverse relation, pursuant to which the
functioning of the cellular clock in peripheral tissues is
modulated by hormones and regulators of carbohydrate
exchange, reductive-oxidative state of the cytoplasm
and glucose level.
However, not only cytoplasmatic and nuclear
factors affect the gene expression of the first stages of
glucose metabolism. Endoplasmatic network is one of
key organelles in the cellular response to ischemia,
hypoxia and some chemicals, activating the complex
set of signaling pathways, reacting towards unfolded
protein. This adaptive reaction is activated in condi-
tions of accumulating unfolded proteins in endoplas-
matic reticulum and is mediated by three resident
EPR-sensors, PERK (PRK-like ER kinase), IRE1/
/ERN1 (inositol-requiring1/endoribonuclease 1) and
ATF6 (activation transcriptional factor 6), but ERN1 is
the main sensor [82, 83].
The activation of unfolded protein response (UPR)
limits the release of new proteins to the endoplasmatic
network and facilitates both protein folding in the
endoplasmatic reticulum and the degradation, which is
essential for cell adaptation, or, on the contrary, induces
the programs of cellular death via mechanisms, related
to the endoplasmatic network [82, 84]. UPR is involved
in the launch of cellular response to the accumulation of
unfolded proteins in the opening of the endoplasmatic
reticulum, occurring in both physiological and patho-
logical conditions.
Two different catalytic domains of bifunctional
signaling enzyme ERN1 were determined to be se-
rine/threonine kinase and endoribonuclease, involved
in ERN1-signaling. Kinase ERN1 autophosphorylates
this enzyme, which results in its dimerization, activa-
tion of endoribonuclease domain and splicing of
mRNA XBP1 (X-Box-binding protein 1) [83]. Mature
splice-variants of mRNA XBP1 encode the transcrip-
tional factor with modified C-terminal amino acid seq-
uence and stimulate the expression of hundreds of spe-
cific genes, responding to unfolded or misfolded pro-
teins [82, 83].
Moreover, during its growth a tumor requires the
functional signaling system of endoplasmatic reticulum
stress as well as hypoxia and ischemia for
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neovascularization and growth. Therefore, a complete
blocking of the ERN1 signal transfer pathway has an
antitumor effect [85, 86]. The signaling pathway of
endoplasmatic reticulum, activated in response to
stress-reaction, is conditioned by the process of
neovascularization, tumor growth and differentiation as
well as death of cells [86].
Another system of regulating gene expression,
including the glycolytic pathway, is related to HIF
(hypoxia-inducible factor). In conditions of hypoxia
the processes of formation of new capillary network are
initiated; there is activation of metabolism processes,
glycolysis, in particular [88], aimed at the adaptation of
cells to hypoxia, which is considerably mediated by the
activation of the transcriptional factor HIF [89].
Hypoxic effects were revealed to depend largely on the
functional state of the ERN1 signaling enzyme system.
It was demonstrated that the level of expression of
hexokinase-2 in conditions of hypoxia and ischemia is
conditioned by the function of ERN1 signaling enzyme
(Figure) [87, 90].
The level of mRNA HK1 in glioma cells is known
to increase in conditions of hypoxia and while culti-
vating cells in glucose-free medium. In addition, the
cultivation of cells in glutamine-free medium evokes
considerable modification of the level of mRNA HK1
in them. The inactivation of gene ERN1 does not result
in considerable change in the level of mRNA of hexo-
kinase-1, but it eliminates the dependence of the ex-
pression of this gene on hypoxia and decreases the ef-
fect of glucose deficiency in the medium of cultivating
cells on its expression level.
At the same time, in hypoxia conditions the level of
HK2 gene expression in glioma cells increases six times
compared to HK1 gene, and twice – in glucose-free
medium. In addition, the level of HK2 gene expression
increases due to the cultivation of glioma cells in
glutamine-free medium. The exclusion of gene ERN1
increases the expression of HK2 gene and eliminates
the dependence of the expression of the latter on the
deficiency of glucose and glutamine in the medium of
cultivating cells, also decreasing the effect of hypoxia
on the expression level. The expression of glucoso-6-
phosphate dehydrogenase gene in glioma cells is in-
creased in case of ERN1 gene exclusion, activating con-
siderably in conditions of hypoxia and glutamine defi-
ciency. Thus, the level of expression for genes HK1 and
HK2 in glioma cells is considerably changed in condi-
tions of hypoxia and ischemia and depends on the fun-
ction of the gene of ERN1 signaling enzyme [87, 90].
The level of mRNA expression of glucoso-6-pho-
sphate dehydrogenase is not impaired in glioma cells
with inhibited function of the enzyme ERN1, but hypo-
xia decreases the expression of G6PDH considerably,
while in conditions of glutamine and glucose defici-
ency there is a registered increase in the expression
level of mRNA G6PDH in both types of glioma cells.
This effect is most expressed in the control glioma cells
in conditions of glutamine deficiency and in the cells
with inhibited function of ERN1 in conditions of
glucose deficiency [87, 90].
Therefore, the signaling system of endoplasmatic
reticulum stress, HIF system and the system of cir-
cadian clock have regulatory effect on the course of
glycolysis and pentose phosphate shunt via the
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Stress factors: hypoxia, ischemia, reductive-oxidative state of
cytoplasm, low-molecular compounds – inhibitors and activators
UPR ERN1
HIF CLOCK
PFKFB
HK1, 2, 3 HK4 G6PDH
Glycolysis amplification, activation of pentose phosphate shunt:
NADPH
+
+ H
+
and ATP, pentose, pyruvate or lactate.
CONSEQUENCE: ADAPTATION, SURVIVAL AND DIVISION OF
CELLS
Figure. Regulatory effect on gene expression of hexokinases and
glucoso-6-phosphate dehydrogenase of cell signaling systems
Legends: UPR ERN1 – system of endoplasmatic reticulum stress; HIF
– hypoxia-inducible factor; CLOCK – circadian clock system; PFKFB
– 6-phosphofructo-2-kinase/fructoso-2,6-bisphosphatase; HK1,2,3,
HK4 – hexokinases; G6PDH – glucoso-6-phosphate dehydrogenase
regulation of mRNA expression for a number of key
glycolysis enzymes. Therefore, the study of the ex-
pression of genes, controlling glucose metabolism, is
an urgent trend of biochemical investigations, as it will
allow revealing molecular mechanisms of expression
regulation for these genes and the interaction of diffe-
rent genes, involved in carcinogenesis as well as ela-
borating new approaches to the creation of antitumor
preparations.
Ð. Þ. Ìàðóíè÷
Ðåãóëÿö³ÿ åêñïðåñ³¿ ãåí³â ãåêñîê³íàç ³ ãëþêîçî-6-ôîñôàòäåã³äðîãå-
íàçè çà óìîâ
íîðìè ³ ïàòîëîã³¿
ÍÍÖ «²íñòèòóò á³îëîã³¿» Êè¿âñüêîãî íàö³îíàëüíîãî óí³âåðñèòåòó
³ìåí³ Òàðàñà Øåâ÷åíêà
Âóë. Âîëîäèìèðñüêà, 64/13, Êè¿â, Óêðà¿íà, 01601
Summary
Ïîñèëåííÿ ãë³êîë³çó ó ïóõëèíàõ çà àåðîáíèõ óìîâ â³äîìå ÿê ôåíî-
ìåí Âàðáóðãà, ïðè öüîìó çíà÷íî àêòè âó- ºòüñÿ ïåíòîçîôîñôàò-
íèé øóíò. Ïåíòîçîôîñôàòíèé øóíò ³ ãë³êîë³ç, îñîáëèâî ¿õí³
ïåðø³ ëàíêè òà ðå- ãóëÿòîðíèé ôåðìåíò 6-ôîñôîôðóê-
òî-2-ê³íàçà/ôðóêòîçî-2,6-á³ñôîñôàòàçà ï³ääàþòüñÿ âïëèâó ñèã-
íàëüíèõ ñèñòåì êë³òèíè, òàêèõ ÿê öèðêàä³àëüíèé ãîäèííèê,
ã³ïîêñ³ÿ-³íäóêóþ÷èé ôàêòîð ³ ñòðåñ åíäî- ïëàçìàòè÷íîãî ðåòè-
êóëóìó. Öå äîçâîëÿº îíêîòðàíñôîðìîâàíèì êë³òèíàì àäàïòóâà-
òèñÿ äî ñòðåñîâèõ ÷èííèê³â, ñåðåä ÿêèõ ã³ïîêñ³ÿ, ³øåì³ÿ ³ ä³ÿ
íèçüêîìîëåêóëÿðíèõ àãåíò³â. Çðîáëåíî àíàë³ç âïëèâó ñèãíàëüíèõ
ñèñòåì íà åêñïðåñ³þ ãåí³â êëþ÷îâèõ ôåðìåíò³â ãë³êîë³çó ³ ïåíòî-
çîôîñôàòíîãî øóíòó çà íîðìàëüíèõ óìîâ òà çà óìîâ îíêî-
ëîã³÷íî¿ ïàòîëîã³¿. Äîñë³äæåíî çíà÷åííÿ öüîãî âïëèâó äëÿ
âèæèâàííÿ îíêîòðàíñ- ôîðìîâàíèõ êë³òèí çà ñòðåñîâèõ óìîâ.
Êëþ÷îâ³ ñëîâà: ãåêñîê³íàçè, ãëþêîçî-6-ôîñôàòäåã³äðîãåíàçà,
åêñïðåñ³ÿ ãåí³â, ñòðåñ.
Ð. Þ. Ìàðóíè÷
Ðåãóëÿöèÿ ýêñïðåññèè ãåíîâ ãåêñîêèíàç è ãëþêîçî-6-
ôîñôàòäåãèäðîãåíàçû â óñëîâèÿõ íîðìû è ïðè ïàòîëîãèè
Ðåçþìå
Óñèëåíèå ãëèêîëèçà â îïóõîëÿõ ïðè àýðîáíûõ óñëîâèÿõ èçâåñòíî
êàê ôåíîìåí Âàðáóðãà, ïðè ýòîì òàêæå çíà÷èòåëüíî âîçðàñòà-
åò àêòèâíîñòü ïåíòîçîôîñôàòíîãî øóíòà. Ïåíòîçîôîñôàò-
íûé øóíò è ãëèêîëèç, îñîáåííî èõ ïåðâûå çâåíüÿ è ðåãóëÿòîðíûé
ôåðìåíò 6-ôîñôîôðóêòî-2-êèíàçà/ôðóêòîçî-2,6-áèñôîñôàòà-
çà ïîäâåðãàþòñÿ âëèÿíèþ ñèãíàëüíûõ ñèñòåì êëåòêè, òàêèõ êàê
öèðêàäèàëüíûå ÷àñû, ãèïîêñèÿ-èíäóöèðóþùèé ôàêòîð è ñòðåññ
ýíäîïëàçìàòè÷åñêîãî ðåòèêóëóìà, ÷òî ïîçâîëÿåò îíêîòðàíñôîð-
ìèðîâàííûì êëåòêàì àäàïòèðîâàòüñÿ ê ñòðåññîâûì ôàêòîðàì,
â ÷àñòíîñòè, èøåìèè è äåéñòâèþ íèçêîìîëåêóëÿðíûõ àãåíòîâ.
Ïðîâåäåí àíàëèç âëèÿíèÿ ñèãíàëüíûõ ñèñòåì íà ýêñïðåññèþ ãåíîâ
êëþ÷åâûõ ôåðìåíòîâ ãëèêîëèçà è ïåíòîçîôîñôàòíîãî øóíòà
ïðè íîðìàëüíûõ óñëîâèÿõ è ïðè ïàòîëîãèè. Èññëåäîâàíî çíà÷åíèå
ýòîãî âëèÿíèÿ äëÿ âûæèâàíèÿ îíêîòðàíñôîðìîâàíèõ êëåòîê â
ñòðåññîâûõ óñëîâèÿõ.
Êëþ÷åâûå ñëîâà: ãåêñîêèíàçû, ãëþêîçî-6-ôîñôàòäåãèäðîãåíà-
çû, ýêñïðåññèÿ ãåíîâ, ñòðåññ.
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